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ABSTRACT
With use of an enzyme-linked immunosorbent
assay (ELISA), Chlamydia pneumoniae immuno-
globulins were detected in a consecutive series of
patients’ sera (n ¼ 122 for IgA and IgG; n ¼ 138
for IgM). When the ELISA tests were repeated, the
percentage disagreements were 12%, 16% and
10% for C. pneumoniae IgA, IgG and IgM, respect-
ively. The reproducibility of the ELISA, expressed
as kappa values, for IgA, IgG and IgM was 0.73,
0.60 and 0.53, respectively (p < 0.001). It was
concluded that the ELISA had good reproduci-
bility for detecting C. pneumoniae IgA, and mod-
erately good reproducibility for detecting C.
pneumoniae IgG and IgM.
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The association between Chlamydia pneumoniae
and atherosclerotic vascular diseases has been
investigated extensively by means of seroepide-
miological observations, pathological specimen
examinations, animal models, immunological and
molecular studies, and antibiotic intervention
studies [1], but seroepidemiology was the ﬁrst
and most commonly used method. Most sero-
epidemiological studies have used micro-
immunoﬂuorescence (MIF), although a few have
employed enzyme-linked immunosorbent assays
(ELISAs). In this study, the reproducibility of
ELISA tests for detection of C. pneumoniae anti-
bodies was investigated in a case-control study on
the seroprevalence of C. pneumoniae in elderly
stroke patients and general medical patients.
Sera were obtained from a consecutive series
of 187 elderly acute stroke patients and control
general medical patients (median age 80 years)
recruited prospectively [2] at a large district
general hospital in East London, UK. Sera were
stored at ) 20 C before analysis.
Commercial ELISA kits (SeroCP; Savyon Diag-
nostics, Ashdod, Israel) were used. The antigens
in these kits originated from puriﬁed C. pneumo-
niae elementary bodies (TW 183), to enable spe-
ciﬁc and sensitive detection of C. pneumoniae IgA,
IgG and IgM. Sera for IgM testing were pre-
treated with the manufacturer’s serum diluent,
containing anti-IgG, to remove rheumatoid factor
and reduce IgG interference. Each serum was
diluted 1:105 with the supplied diluent, as recom-
mended by the manufacturer. The case or control
status of the sera was blinded during analyses
performed by two experienced investigators.
Only the ﬁrst 122 consecutive patients’ sera were
examined for C. pneumoniae IgA and IgG, and
138 for IgM. The serological tests were then
repeated, and the results analysed to establish
the reproducibility.
Determination and validation of test results
were in accordance with the manufacturer’s
instructions. Absorbance or optical density (OD),
proportional to the amount of speciﬁc antibodies
bound to the coated antigens in each plate, was
read at 450 nm. For a valid test, two criteria were
met: (1) OD450 of the positive control ‡ 0.8; and
(2) mean OD450 of the negative control 0.1–0.4. In
order to normalise the results from different
tests, a cut-off index (COI) was calculated, in
which COI ¼ serum sample OD450 ‚ cut-off va-
lue (COV), and where COV ¼ twice the mean of
two negative control OD450 readings. As deﬁned
by the manufacturer, a COI of < 1.0 was
negative, a COI of 1–1.1 was borderline, and a
COI of > 1.1 was positive. The manufacturer
suggests that if borderline results are obtained
from two specimens taken from the same patient
2–4 weeks apart, the specimens should be con-
sidered negative. However, in the present study,
second serum samples were not collected, and
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therefore a single borderline result was deﬁned
as negative.
The COI of positive samples ranged from 1.15
to 6.16 for C. pneumoniae IgA, from 1.12 to 4.91 for
IgG, and from 1.12 to 5 for IgM. In the repeat tests,
the COI of positive samples ranged from 1.14 to
5.23 for IgA, from 1.101 to 3.45 for IgG, and from
1.20 to 3.49 for IgM. Table 1 shows the COI values
Table 1a. Cut-off index (COI):
samples with borderline COI in the
ﬁrst run with repeat results
Sample
IgA
Sample
IgG
Sample
IgM
1st run 2nd run 1st run 2nd run 1st run 2nd run
37 1.05 0.46 107 1.08 2.12 17 1.00 0.99
39 1.09 0.83 115 1.08 1.70 25 1.10 0.45
56 1.04 0.69 30 1.08 0.53
74 1.09 1.17 45 1.09 0.63
99 1.10 0.50 54 1.04 0.92
104 1.05 1.17 60 1.04 0.97
83 1.06 1.04
114 1.03 1.23
119 1.00 1.57
Mean 1.07 0.80 1.08 1.91 1.05 0.93
Table 1b. Cut-off index (COI):
samples with borderline COI in the
second run with ﬁrst-run results
Sample
IgA
Sample
IgG
Sample
IgM
2nd
run
1st
run
2nd
run
1st
run
2nd
run
1st
run
10 1.02 1.85 80 1.07 1.85 83 1.04 1.06
78 1.08 1.27 136 1.02 0.71
110 1.03 1.17 138 1.01 0.54
Mean
Overall
1.04 1.43 1.02 0.77
Mean 1.06 1.01 1.08 1.89 1.04 0.89
Table 1c. Cut-off index: samples
giving discrepant results in the ﬁrst
and second runs
Sample
IgA
Sample
IgG
Sample
IgM
1st run 2nd run 1st run 2nd run 1st run 2nd run
10 1.85 1.02 5 0.93 1.29 2 1.22 0.46
17 1.37 0.71 17 1.47 0.79 3 1.21 0.55
28 1.51 0.75 21 1.44 0.90 6 1.58 0.60
44 1.15 0.40 47 2.04 0.68 8 1.23 0.64
74 1.09 1.17 48 0.83 1.28 24 1.12 0.78
78 1.27 1.08 50 3.56 0.80 27 1.29 0.61
80 1.67 0.98 56 0.80 1.96 29 2.52 0.91
91 1.15 0.66 65 1.13 0.59 31 1.93 0.70
95 1.40 0.89 66 4.13 0.39 37 1.25 0.65
96 2.64 0.95 80 1.85 1.07 41 1.19 0.66
98 1.63 0.71 90 2.71 0.78 42 1.25 0.66
104 1.05 1.17 95 0.71 1.43 98 0.64 1.20
110 1.17 1.03 97 0.60 1.44 114 1.03 1.23
117 0.96 1.16 102 0.80 1.17 119 1.00 1.57
122 0.89 1.81 106 0.76 1.25
107 1.08 2.12
113 0.96 1.101
115 1.08 1.70
117 0.92 1.38
122 0.89 2.12
Mean 1.39 0.97 1.43 1.21 1.32 0.80
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of samples giving borderline or discrepant results.
The ELISA reproducibility results are summa-
rised in Table 2.
Serological testing is considered the most
useful means of determining the prevalence of
C. pneumoniae infection [3]. MIF is currently the
standard in C. pneumoniae serology, but is
subjective and requires an expert microscopist
to interpret the results [3,4]. Inter-laboratory
variation of MIF shows an overall agreement
with reference standard titres of c. 80% [5]. In
comparison, ELISA is more objective than MIF
[3]. It can be automated, with the advantages of
high throughput and electronic records. ELISA
is therefore easier to standardise and is the
preferred diagnostic method [4]. However,
although there is good agreement between
serological tests and detection of C. pneumoniae
by PCR or culture [6], others have reported a
poor correlation between C. pneumoniae serology
and culture [7].
In the clinical setting, interpretation of serolog-
ical results should be based on a combination of
C. pneumoniae IgA, IgG and IgM proﬁles. Positive
IgM, negative or positive IgG, and negative or
positive IgA results indicate current infection.
Positive IgG, and negative IgM and IgA results
indicate past or current infection. Positive IgA,
with positive or negative IgG and negative IgM
results indicate current or chronic infection.
However, samples obtained early during primary
infection may not contain detectable antibodies. If
C. pneumoniae infection is suspected, a second
sample should be obtained 2–4 weeks later and
tested in parallel with the original sample. How-
ever, all clinical and laboratory data should be
considered when making a diagnosis.
The SeroCP ELISA result is qualitative, and is
reported on the basis of a single 1:105 dilution of a
serum sample, and not as an endpoint titre.
According to the manufacturer, overall agreement
between in-house MIF and SeroCP ELISA is 98%
for IgA, 95% for IgG, and 89% for IgM. Others
have also reported a moderately good correlation
between MIF results and ELISA tests (r0.8, p0.001)
[4,8]. Similarly, as in other studies [9,10], the
sensitivity and speciﬁcity compared to MIF were
reported to be c. 90% by the manufacturer.
However, ELISA reproducibility needs proper
evaluation, and this was the focus of the current
study.
A previous study reported good reproducibil-
ity for the Labsystem ELISA kit for detection of
C. pneumoniae IgG, with mean and median coef-
ﬁcients of variation of 10.2% and 8.6%, respect-
ively [8]. The present study was the ﬁrst
to evaluate the reproducibility of the SeroCP
ELISA, and the results in Table 2 demonstrated a
good sample agreement of > 80%, similar to that
reported for MIF [5]. The kappa value quantiﬁes
the agreement between the ﬁrst and repeated
ELISA tests, after allowing for random variation
and the number of observations used [11].
A kappa value of 0 indicates no agreement,
whereas 1.0 indicates perfect agreement. If
0.61 < kappa < 0.80, good concordance is indi-
cated, while 0.41 < kappa < 0.60 indicates mod-
erate concordance. The kappa values for the
SeroCP ELISA were 0.73 for IgA, 0.60 for IgG,
and 0.53 for IgM (p < 0.001). It was concluded that
the SeroCP ELISA has good reproducibility for
IgA, and moderately good reproducibility for IgG
and IgM.
ELISA may become a preferred objective test
in the seroepidemiological study of C pneumoniae
infection and its link with atherosclerotic vascu-
lar disease. Whether the results obtained by
ELISA correlate with endovascular chronic infec-
Table 2. ELISA reproducibility
Chlamydia
pneumoniae
antibody
Both
tests
negative
Both
tests
positive
One test
negative or
borderline,
one positive
% sample
disagreement
(95% CI)
Kappa
value
IgA
(n ¼ 122)
36 71 15 12%
(6–18%)
0.73
(p < 0.001)
IgG
(n ¼ 122)
25 77 20 16%
(9–23%)
0.60
(p < 0.001)
IgM
(n ¼ 138)
114 10 14 10%
(5–15%)
0.53
(p < 0.001)
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tion remains controversial. However, further
efforts to standardise new commercially avail-
able ELISA kits against MIF will be required
[3,12]. Although the SeroCP ELISA is comparable
to MIF, its level of reproducibility is not perfect,
and this fact should be considered when such a
kit is used in further epidemiological or diag-
nostic studies.
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ABSTRACT
Differences in inﬂammatory responses in human
adult whole blood to live pneumococcal serotypes
3, 7F, 9V and 23F were investigated. Using ﬂow
cytometry and ELISA, oxidative burst, expression
of activation markers CD11b ⁄CD18, and in-vitro
production of tumour necrosis factor-a, interleu-
kin-6 (IL-6) and interleukin-8 were measured.
There was no signiﬁcant difference between the
serotypes regarding any of the variables investi-
gated, although there was a trend towards higher
concentrations of IL-6 induced by serotypes 9V
and 23F. In the present experimental model, the
serotypes of Streptococcus pneumoniae shown pre-
viously to cause different degrees of inﬂammation
were found to cause a similar inﬂammatory
response in human whole blood.
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oxidative burst, cytokine response
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